Advertisement
Common Law Admission Test

CLAT 2024: Registration window concludes today; check how to apply inside

Our Correspondent
Posted on 03 Nov 2023
13:03 PM
File Image
Summary
The registration process commenced on 1 July 2023
Candidates who want to apply for the Common Law Admission Test can do it through the official website of the Consortium of NLUs- consortiumofnlus.ac.in

The Consortium of NLUs will end the registration window for CLAT 2024 on 3 November 2023. Candidates who want to apply for the Common Law Admission Test can do it through the official website of the Consortium of NLUs- consortiumofnlus.ac.in.

The registration process commenced on 1 July 2023. The application fees for General/OBC/PWD/NRI candidates is Rs 4000 and the application fee for SC/ST/BPL category candidates is Rs 3500.

CLAT 2024 Registration: Steps to apply

Advertisement
  1. Go to the official website- consortiumofnlus.ac.in
  2. On the homepage, click on the CLAT 2024 registration link available
  3. Key in the required login details and click submit
  4. Fill in the application form and pay the application fees
  5. Submit and download the page
  6. Take a printout of the same for future reference

As per the schedule, the examination will be conducted on 3 December 2023, from 2 pm to 4 pm. 

The Common Law Admission Test (CLAT) is a national-level entrance exam for admissions to undergraduate (UG) and postgraduate (PG) law programs offered by 22 National Law Universities in India.

Last updated on 03 Nov 2023
01:03 PM
Common Law Admission Test Registration Date law National Law University
Advertisement
Similar stories
Legal education

UGC Pushes NLUs, Law Colleges Towards Forensic-Based Learning; Asks to Integrate BNS . . .

Bihar School Examination Board

BSEB Opens Grievance Redressal Centres and Online Complaint Portal for Exams, Board I. . .

NEET UG 2026

NEET UG 2026 Re-Exam: Check Fee Refund Portal Update by NTA and Reimbursement Steps

CBSE 2026

CBSE Calls Class 12 OSM Evaluation Allegations ‘Factually Incorrect’; Refutes Med. . .

read next